Clarity Pharmaceuticals

Performance

About Clarity Pharmaceuticals

Clarity Pharmaceuticals is a clinical-stage radiopharmaceutical company developing next-generation theranostic products for oncology, leveraging SAR Technology and copper isotopes to enable targeted imaging and therapy. The company focuses on cancers such as prostate cancer, neuroblastoma, neuroendocrine tumours, and breast cancer, with an emphasis on improving treatment outcomes for both adults and children. Headquartered in Australia, Clarity’s pipeline includes copper-64 diagnostic and copper-67 therapeutic candidates designed to address manufacturing and logistical challenges in radiopharmaceuticals while expanding the oncology radiopharmacy landscape.